Showing posts with label rhesus macaque. Show all posts
Showing posts with label rhesus macaque. Show all posts

Wednesday, 6 January 2016

Zika virus, mosquitoes and a monkey on a platform...

UPDATED: 07JAN2016 AEST
As I noted yesterday the first published description of the isolation of Zika virus was from a study set up in the Zika forest in Uganda. It was described in print by Dr George Dick and colleagues in the September 1952 issue of Transactions of the Royal Society of Tropical Medicine and Hygiene.[1]

Rhesus macaque (Macaca mulatta) [2]
In the first study, which began April 1947, six platforms were set up in the forest canopy and upon each, a caged rhesus monkey was placed. 

The first Zika virus was identified from a monkey...

This was to be a Yellow fever virus (YFV) study since Zika forest was known to harbour a lot of previously YFV infected, antibody-positive monkeys-but stuff happens on the road to completing a good plan.

By the way: placing or penning an animal in a location known to, or under suspicion of, harbouring an infectious agent - a virus in this case - is the precess of creating a sentinel animal.

On 18th April, the daily temperature recording for "Rhesus 766" had increased to 39.7'C, rising to 40'C the next day. It was taken to the lab at Entebbe, a blood sample collected and then the primate was observed for the next month. The only sign or symptom of illness in 766 was the fever.

The blood was injected intraperitoneally (no signs of illness) or intracerebrally (became ill from day 10 post-injection) into mice and underneath the skin of Rhesus 771 (which did not develop any signs of illness).

A filterable "agent" (filters were used to remove everything but very small viruses) was recovered from the brains of the ill mice and also from the serum of 766 - it was later named Zika virus (766 strain). The virus's growth could be hampered by antibodies which developed in the serum of 766 a month later, identifying the that the Zika virus was capable of triggering a specific immune response, despite a mild illness. The more lab-savvy of you may have realised by now, that this all happened before cell culture was being used. The only way to "grow" or amplify more virus was to infect anew a susceptible host animal-which could also reveal whether the agent was capable of causing disease, so long as the experiments were suitably controlled.

A second Zika virus was found among mosquitoes...

A second virus (later called strain E/1) was acquired during a different study, but also set up for YFV. The E/1 was identified from a ground up, unfiltered preparation of Aedes africanus mosquitoes in saline which had been caught 11-12th January 1948 using a variation of the platform system. . The preparation was injected intracerebrally into 6 mice and subcutaneously into Rhesus 758 via 9 inoculations, across 2 weeks. 

Diagnosis of Zika virus by infection of animals...

Primate 758 showed no signs of illness, but the mice had - at the 7th day - so at day 8, 9 and 10 after 758's injection, blood was collected and serum injected intracerebrally into groups of 6 new mice. 
  • From the first primate sample (day 8), 2 injected mice died and virus could be passed on to additional mice from filtered preparations of their infected brain tissue
  • From the second sample (day 9), 1 mouse died (and its brain tissue filtrate could also produce new infections in mice). A second mouse was paralysed but another virus, called Theiler's mouse encephalitis virus [TMEV], a picornavirus, was identified upon further infections 
  • No mice died from the 3rd 758 inoculation of serum
  • The serum from 758 was shown to block infection of animals by Zika virus after it was first preincubated with preparations of:
    • the agent isolated from 758 serum after inoculation with the A. africanus preparation or
    • the E/1 Zika virus strain or
    • the 766 Zika virus strain
The authors concluded Zika virus was a new virus and that it triggered a specific antibody response which did not cross-react with YFV, dengue virus or the TMEV found in the paralysed mouse. 

It was also notable that disease was mild or went unnoticed in primates. Primates are usually considered to be close animal substitutes for humans in studies of disease progression. 

No studies of pregnant primates were conducted which does raise the question of whether we should consider a check-list of things to research for each and every virus capable of replicating in us.

References...
  1. Zika virus. I. Isolations and serological specificity.
    DICK GW, KITCHEN SF, HADDOW AJ.
    Trans R Soc Trop Med Hyg. 1952 Sep;46(5):509-20.
    http://www.ncbi.nlm.nih.gov/pubmed/12995440.
  2. https://www.flickr.com/photos/wild_speedy/4185543087/
Updates..
  1. Added some links and worked out some typos and layout issues.

Monday, 9 September 2013

Combined interferon and ribavirin therapy an option for early MERS-CoV intervention?

Falzarano and colleagues write in Nature Medicine that the combination of ribavirin (an antiviral) and interferon-α2b (a cytokine key to our antiviral defenses) improved the health of MERS-CoV (EMC/2012) inoculated rhesus macaque monkeys. 

This builds on the March Study by Falzarano et al, which reported  the usefulness of this drug cocktail in reducing virus production in a cell culture system.

Treated infected animals did not suffer from increased respiratory rate, breathing difficulties or increased white blood cell counts (mostly due to neutrophils). Treated infected animals also showed no X-Ray changes in their lungs 1-day after infection and little change beyond that. Untreated animals showed mild to marked evidence of pneumonia and also lower levels of markers of inflammation and copies of viral RNA genome.

The macaques were inoculated with 106 tissue culture infective doses (TCID50) by combined intratracheal (lower respiratory tract), intranasal (upper respiratory tract), oral (ingestion) and ocular routes. That seems to represent a fairly "shock-and-awe" cocktail of inoculation routes compared to how humans may get exposed. Viral RNA was detected in spleen, kidney, lymph nodes, upper and lower respiratory tract and airways in the untreated animals - and many of those sites in the treated ones. The relevance of this study to MERS-CoV transmission is probably limited, but then it's not a transmission study, it's a treatment study. There is another article cited as in press from part of this group. It may further address tissue replication; Novel human betacoronavirus causes a transient lower respiratory tract infection in a rhesus macaque model. Proc. Natl. Acad. Sci. USA.

Interestingly, disease in the macaques is at best mild to moderate in severity, so how the drug cocktail would work when faced with severe human disease...which may take longer to develop...remains unclear. Also unclear, is what disease would look like in macaques with a similar degree of comorbidities to those seen in the most severe human MERS cases.

The main proviso is, the cocktail must be administered early; it was administered 8-hours after infecting the monkeys here. 

With a 5-working day to 2-week turnaround in testing for MERS-CoV, treatment would have to be started at first suspicion and even then might not meet this window. Given the Qatar GP story yesterday, that window would be long shut, painted over and boarded up.

Nonetheless, this is a very encouraging finding and a very nice piece of work that adds an important step in the path to providing a therapeutic option to MERS-CoV infections.